ZDHHC9 demonstrates selectivity for:
Transgenic ZDHHC9 overexpression in mice causes:
ZDHHC9 mutations linked to:
Small-molecule inhibitors
Gene therapy strategies
High ZDHHC9 expression reduces median glioblastoma survival from 1380 to 436 days (HR=2.89)
Plasma ZDHHC9 levels predict heart failure progression (AUC=0.81)
Recombinant Bovine Palmitoyltransferase ZDHHC9 (ZDHHC9) is a palmitoyltransferase that catalyzes the addition of palmitate to various protein substrates. The ZDHHC9-GOLGA7 complex specifically palmitoylates HRAS and NRAS. ZDHHC9 may also palmitoylate the β-2 adrenergic receptor (ADRB2), thereby modulating G protein-coupled receptor signaling.